4//SEC Filing
Skvarka Jan 4
Accession 0001104659-21-141737
CIK 0001616212other
Filed
Nov 18, 7:00 PM ET
Accepted
Nov 19, 1:20 PM ET
Size
10.6 KB
Accession
0001104659-21-141737
Insider Transaction Report
Form 4
Skvarka Jan
DirectorPresident and CEO
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2021-11-17−197,000→ 0 totalExercise: $0.30Exp: 2029-11-07→ Common Shares (197,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-11-17−1,162,500→ 0 totalExercise: $0.43Exp: 2029-09-25→ Common Shares (1,162,500 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2021-11-17−600,000→ 0 totalExercise: $12.03Exp: 2030-12-23→ Common Shares (600,000 underlying)
Footnotes (3)
- [F1]On November 17, 2021 (the "Closing Date"), PF Argentum Acquisition ULC, an indirect wholly owned subsidiary of Pfizer, Inc. (the "Purchaser") acquired all of the outstanding common shares of Trillium Therapeutics Inc. (the "Issuer") under a plan of arrangement pursuant to the Canada Business Corporations Act (British Columbia) (the "Plan of Arrangement"), whereby Issuer became a wholly owned subsidiary of the Purchaser. At the Effective Time (the "Effective Time") of the Plan of Arrangement, all common shares and equity awards of the Issuer that were issued and outstanding immediately prior to the Effective Time were converted into the right to receive $18.50 per share in cash.
- [F2]The exercise price of these options is $0.38 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
- [F3]The exercise price of these options is $0.54 CAD and has been translated to USD in the table above at an exchange rate of $1.00 CAD to $0.79 USD
Documents
Issuer
Trillium Therapeutics Inc.
CIK 0001616212
Entity typeother
Related Parties
1- filerCIK 0001838042
Filing Metadata
- Form type
- 4
- Filed
- Nov 18, 7:00 PM ET
- Accepted
- Nov 19, 1:20 PM ET
- Size
- 10.6 KB